Insmed slides 6% as brensocatib HS trial miss continues to weigh
Insmed shares fell about 6% on April 25, 2026 as selling pressure lingered after the company’s April 7 announcement that its Phase 2b CEDAR trial of brensocatib in hidradenitis suppurativa missed both primary and secondary endpoints. With no new company release today, the move looks driven by continued de-risking and positioning ahead of Insmed’s next earnings report expected around April 30, 2026.
1. What’s moving the stock today
Insmed (INSM) is down about 6% in Friday trading (April 25, 2026) with no fresh company press release identified today. The decline appears to be an aftershock of the April 7, 2026 clinical update showing brensocatib failed in the Phase 2b CEDAR study in hidradenitis suppurativa (HS), missing both primary and secondary efficacy endpoints in both tested dose arms, prompting Insmed to discontinue the HS development program for brensocatib. (investor.insmed.com)
2. The key overhang: discontinued HS program
The April 7 update is still being repriced by investors because it removes a potential growth path for brensocatib and underscores development risk when expanding into new indications. Insmed has said it plans to present the CEDAR data at a future medical congress, but the topline miss and program discontinuation are the main negative fundamental datapoints in the near-term narrative. (investor.insmed.com)
3. Why the timing matters now
The move is also landing as the market looks toward Insmed’s next earnings report window, with widely followed calendars pointing to late April 2026 (commonly listed as April 30, 2026). That setup can amplify volatility as investors reduce exposure, rebalance into other biotech catalysts, or reassess valuation after a major pipeline disappointment. (investing.com)
4. What to watch next
Near term, investors will focus on management’s commentary around capital allocation and pipeline priorities post-CEDAR, plus any updated timelines for other clinical programs and commercial execution. With the HS indication shelved for brensocatib, the market’s next test is whether upcoming earnings and guidance reinforce confidence in Insmed’s remaining growth drivers enough to stabilize the shares. (investor.insmed.com)